drugset / Trial / NCT01470742
Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of the trial is to compare Overall survival between capecitabine plus oxaliplatin (XELOX) and capecitabine (X) as first-line chemotherapy in elderly patients with advanced gastric cancer.
Timeline
- Start
- 2010-09
- Primary completion
- 2015-02
- Completion
- 2015-12
Outcome
Outcome not reported
Stopped: “We stop because of problems such as insurance.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 110 mg/m2 | — |
| Comparator | Capecitabine | Small molecule | 1000 mg/m2 | — |